Antonella Castagna

List of Publications by Year
in descending order

346 papers	16,839 citations	29994 54 h-index	18606 119 g-index
349 all docs	349 docs citations	349 times ranked	22938 citing authors

#	Article	IF	Citations
1	Compassionate Use of Remdesivir for Patients with Severe Covid-19. New England Journal of Medicine, 2020, 382, 2327-2336.	13.9	2,241
2	A Whole-Genome Association Study of Major Determinants for Host Control of HIV-1. Science, 2007, 317, 944-947.	6.0	1,136
3	Effect of Remdesivir vs Standard Care on Clinical Status at 11 Days in Patients With Moderate COVID-19. JAMA - Journal of the American Medical Association, 2020, 324, 1048.	3.8	1,032
4	Liver-Related Deaths in Persons Infected With the Human Immunodeficiency Virus. Archives of Internal Medicine, 2006, 166, 1632.	4.3	1,004
5	Common Genetic Variation and the Control of HIV-1 in Humans. PLoS Genetics, 2009, 5, e1000791.	1.5	377
6	Efficacy and safety of tocilizumab in severe COVID-19 patients: a single-centre retrospective cohort study. European Journal of Internal Medicine, 2020, 76, 43-49.	1.0	349
7	Epstein-Barr virus DNA in cerebrospinal fluid from patients with AIDS-related primary lymphoma of the central nervous system. Lancet, The, 1993, 342, 398-401.	6.3	330
8	Predictors of trend in CD4-positive T-cell count and mortality among HIV-1-infected individuals with virological failure to all three antiretroviral-drug classes. Lancet, The, 2004, 364, 51-62.	6.3	303
9	Dolutegravir in Antiretroviral-Experienced Patients With Raltegravir- and/or Elvitegravir-Resistant HIV-1: 24-Week Results of the Phase III VIKING-3 Study. Journal of Infectious Diseases, 2014, 210, 354-362.	1.9	284
10	Risk Factors and Outcomes for Late Presentation for HIV-Positive Persons in Europe: Results from the Collaboration of Observational HIV Epidemiological Research Europe Study (COHERE). PLoS Medicine, 2013, 10, e1001510.	3.9	256
11	CD4/CD8 ratio normalisation and non-AIDS-related events in individuals with HIV who achieve viral load suppression with antiretroviral therapy: an observational cohort study. Lancet HIV,the, 2015, 2, e98-e106.	2.1	249
12	Secondary infections in patients hospitalized with COVID-19: incidence and predictive factors. Clinical Microbiology and Infection, 2021, 27, 451-457.	2.8	243
13	Early predictors of clinical outcomes of COVID-19 outbreak in Milan, Italy. Clinical Immunology, 2020, 217, 108509.	1.4	236
14	All-cause mortality in treated HIV-infected adults with CD4 >=500/mm3 compared with the general population: evidence from a large European observational cohort collaborationÂ. International Journal of Epidemiology, 2012, 41, 433-445.	0.9	217
15	Interleukin-6 blockade with sarilumab in severe COVID-19 pneumonia with systemic hyperinflammation: an open-label cohort study. Annals of the Rheumatic Diseases, 2020, 79, 1277-1285.	0.5	212
16	HIV-induced immunodeficiency and mortality from AIDS-defining and non-AIDS-defining malignancies. Aids, 2008, 22, 2143-2153.	1.0	207
17	Polymerase chain reaction on cerebrospinal fluid for diagnosis of virus-associated opportunistic diseases of the central nervous system in HIV-infected patients. Aids, 1996, 10, 951-958.	1.0	184
18	Eosinophils from Physiology to Disease: A Comprehensive Review. BioMed Research International, 2018, 2018, 1-28.	0.9	182

#	Article	IF	Citations
19	Elevated alpha-tumor necrosis factor levels in spinal fluid from HIV-1-infected patients with central nervous system involvement. Annals of Neurology, 1991, 29, 21-25.	2.8	166
20	Microbial translocation predicts disease progression of HIV-infected antiretroviral-naive patients with high CD4+ cell count. Aids, 2011, 25, 1385-1394.	1.0	155
21	Cytomegalovirus Coinfection Is Associated With an Increased Risk of Severe Nonâ€“AIDS-Defining Events in a Large Cohort of HIV-Infected Patients. Journal of Infectious Diseases, 2015, 211, 178-186.	1.9	146
22	CD4 Cell Count and the Risk of AIDS or Death in HIV-Infected Adults on Combination Antiretroviral Therapy with a Suppressed Viral Load: A Longitudinal Cohort Study from COHERE. PLoS Medicine, 2012, 9, e1001194.	3.9	145
23	Cytomegalovirus Infection of the Central Nervous System in Patients with AIDS: Diagnosis by DNA Amplification from Cerebrospinal Fluid. Journal of Infectious Diseases, 1992, 166, 1408-1411.	1.9	141
24	Long-term Mortality in HIV-Positive Individuals Virally Suppressed for >3 Years With Incomplete CD4 Recovery. Clinical Infectious Diseases, 2014, 58, 1312-1321.	2.9	140
25	Interleukin-1 and interleukin-6 inhibition compared with standard management in patients with COVID-19 and hyperinflammation: a cohort study. Lancet Rheumatology, The, 2021, 3, e253-e261.	2.2	140
26	Lamivudine monotherapy in HIV-1-infected patients harbouring a lamivudine-resistant virus: a randomized pilot study (E-184V study). Aids, 2006, 20, 795-803.	1.0	139
27	Prevalence, Associated Factors, and Prognostic Determinants of AIDSâ€Related Toxoplasmic Encephalitis in the Era of Advanced Highly Active Antiretroviral Therapy. Clinical Infectious Diseases, 2004, 39, 1681-1691.	2.9	131
28	Residual clinical damage after COVID-19: A retrospective and prospective observational cohort study. PLoS ONE, 2020, 15, e0239570.	1.1	129
29	Development and Validation of a Risk Score for Chronic Kidney Disease in HIV Infection Using Prospective Cohort Data from the D:A:D Study. PLoS Medicine, 2015, 12, e1001809.	3.9	119
30	Randomized Trial to Evaluate Indinavir/Ritonavir versus Saquinavir/Ritonavir in Human Immunodeficiency Virus Type 1â€“Infected Patients: The MaxCmin1 Trial. Journal of Infectious Diseases, 2003, 188, 635-642.	1.9	118
31	Global Trends in CD4 Cell Count at the Start of Antiretroviral Therapy: Collaborative Study of Treatment Programs. Clinical Infectious Diseases, 2018, 66, 893-903.	2.9	105
32	Fostemsavir in Adults with Multidrug-Resistant HIV-1 Infection. New England Journal of Medicine, 2020, 382, 1232-1243.	13.9	101
33	Mortality in Patients with HIV-1 Infection Starting Antiretroviral Therapy in South Africa, Europe, or North America: A Collaborative Analysis of Prospective Studies. PLoS Medicine, 2014, 11, e1001718.	3.9	100
34	COVID-19 survival associates with the immunoglobulin response to the SARS-CoV-2 spike receptor binding domain. Journal of Clinical Investigation, 2020, 130, 6366-6378.	3.9	97
35	Cerebrospinal fluid S-adenosylmethionine (SAMe) and glutathione concentrations in HIV infection Effect of parenteral treatment with SAMe. Neurology, 1995, 45, 1678-1683.	1.5	95
36	Cross-resistance Profile of the Novel Integrase Inhibitor Dolutegravir (S/GSK1349572) Using Clonal Viral Variants Selected in Patients Failing Raltegravir. Journal of Infectious Diseases, 2011, 204, 1811-1815.	1.9	94

#	Article	IF	Citations
37	The Incidence of AIDS-Defining Illnesses at a Current CD4 Count â‰¥200 Cells/ÂµL in the Postâ€“Combination Antiretroviral Therapy Era. Clinical Infectious Diseases, 2013, 57, 1038-1047.	2.9	92
38	Fast reshaping of intensive care unit facilities in a large metropolitan hospital in Milan, Italy: facing the COVID-19 pandemic emergency. Critical Care and Resuscitation: Journal of the Australasian Academy of Critical Care Medicine, 2020, 22, 91-94.	0.0	87
39	Insights into reasons for discontinuation according to year of starting first regimen of highly active antiretroviral therapy in a cohort of antiretroviralâ€naÃ¯ve patients. HIV Medicine, 2010, 11, 104-113.	1.0	85
40	Genotype and Phenotype Patterns of Human Immunodeficiency Virus Type 1 Resistance to Enfuvirtide during Long-Term Treatment. Antimicrobial Agents and Chemotherapy, 2004, 48, 3253-3259.	1.4	83
41	Death rates in HIV-positive antiretroviral-naive patients with CD4 count greater than 350 cells per Î¼L in Europe and North America: a pooled cohort observational study. Lancet, The, 2010, 376, 340-345.	6.3	82
42	Capsid Inhibition with Lenacapavir in Multidrug-Resistant HIV-1 Infection. New England Journal of Medicine, 2022, 386, 1793-1803.	13.9	82
43	Risk of type 2 diabetes among HIV-infected and healthy subjects in Italy. European Journal of Epidemiology, 2012, 27, 657-665.	2.5	73
44	Late presentation for HIV care across Europe: update from the Collaboration of Observational HIV Epidemiological Research Europe (COHERE) study, 2010 to 2013. Eurosurveillance, 2015, 20, .	3.9	70
45	Bone mineral density and inflammatory and bone biomarkers after darunavirâ€“ritonavir combined with either raltegravir or tenofovirâ€“emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV,the, 2015, 2, e464-e473.	2.1	69
46	Non-AIDS defining cancers in the D:A:D Study - time trends and predictors of survival: a cohort study. BMC Infectious Diseases, 2013, 13, 471.	1.3	68
47	Rapid initiation of antiretroviral therapy at HIV diagnosis: definition, process, knowledge gaps. HIV Medicine, 2019, 20, 3-11.	1.0	68
48	Dynamic patterns of human immunodeficiency virus type 1 integrase gene evolution in patients failing raltegravir-based salvage therapies. Aids, 2009, 23, 455-460.	1.0	66
49	B-cell subset alterations and correlated factors in HIV-1 infection. Aids, 2013, 27, 1209-1217.	1.0	66
50	Hepatitis C virus viremia increases the incidence of chronic kidney disease in HIV-infected patients. Aids, 2012, 26, 1917-1926.	1.0	62
51	Treatment simplification to atazanavir/ritonavirâ€‰+â€‰lamivudine versus maintenance of atazanavir/ritonavirâ€‰+â€‰two NRTIs in virologically suppressed HIV-1-infected patients: 48 week results from a randomized trial (ATLAS-M). Journal of Antimicrobial Chemotherapy, 2017, 72, dkw557.	1.3	62
52	Safety and efficacy of the HIV-1 attachment inhibitor prodrug fostemsavir in heavily treatment-experienced individuals: week 96 results of the phase 3 BRIGHTE study. Lancet HIV,the, 2020, 7, e740-e751.	2.1	58
53	The Appealing Story of HIV Entry Inhibitors. Drugs, 2005, 65, 879-904.	4.9	57
54	Phase 2 double-blind, randomized trial of etravirine versus efavirenz in treatment-naive patients. Aids, 2011, 25, 2249-2258.	1.0	57

#	Article	IF	Citations
55	Incidence of Malignancies in HIVâ€Infected Patients and Prognostic Role of Current CD4 Cell Count: Evidence from a Large Italian Cohort Study. Clinical Infectious Diseases, 2010, 50, 1316-1321.	2.9	56
56	Lopinavir/ritonavir treatment in HIV antiretroviral-experienced patients: evaluation of risk factors for liver enzyme elevation. HIV Medicine, 2004, 5, 334-343.	1.0	55
57	Polymerase chain reaction for Toxoplasma gondii DNA in the cerebrospinal fluid of AIDS patients with focal brain lesions. Aids, 1994, 8, 1691-1694.	1.0	54
58	Osteoprotegerin and bone turnover markers in heavily pretreated HIV-infected patients. HIV Medicine, 2005, 6, 145-150.	1.0	54
59	Risk of Developing Specific AIDSâ€Defining Illnesses in Patients Coinfected with HIV and Hepatitis C Virus With or Without Liver Cirrhosis. Clinical Infectious Diseases, 2009, 49, 612-622.	2.9	53
60	Genotypic/phenotypic patterns of HIV-1 integrase resistance to raltegravir. Journal of Antimicrobial Chemotherapy, 2010, 65, 425-433.	1.3	53
61	Changes in hospital admissions across Europe: 1995-2003. Results from the EuroSIDA study. HIV Medicine, 2004, 5, 437-447.	1.0	52
62	A Randomized Trial to Evaluate Lopinavir/Ritonavir versus Saquinavir/Ritonavir in HIV-1-Infected Patients: The Maxcmin2 Trial. Antiviral Therapy, 2005, 10, 735-743.	0.6	51
63	Infections after Allogenic Transplant with Post-Transplant Cyclophosphamide: Impact of Donor HLA Matching. Biology of Blood and Marrow Transplantation, 2020, 26, 1179-1188.	2.0	49
64	Stavudine or indinavir-containing regimens are associated with an increased risk of diabetes mellitus in HIV-infected individuals. Aids, 2003, 17, 1993-1995.	1.0	48
65	Ganciclovir Therapy for Cytomegalovirus (CMV) Infection of the Central Nervous System in AIDS Patients: Monitoring by CMV DNA Detection in Cerebrospinal Fluid. Journal of Infectious Diseases, 1995, 171, 1603-1606.	1.9	47
66	A comparision of brain biopsy and CSF-PCR in the diagnosis of CNS lesions in AIDS patients. Journal of Neurology, 1996, 244, 35-39.	1.8	47
67	Liver-related death among HIV/hepatitis C virus-co-infected individuals. Aids, 2015, 29, 1205-1215.	1.0	46
68	Effectiveness of dolutegravirâ€based regimens as either firstâ€line or switch antiretroviral therapy: data from the Icona cohort. Journal of the International AIDS Society, 2019, 22, e25227.	1.2	46
69	LC-MS/MS method for simultaneous determination of linezolid, meropenem, piperacillin and teicoplanin in human plasma samples. Journal of Pharmaceutical and Biomedical Analysis, 2019, 169, 11-18.	1.4	46
70	Pulmonary Vascular Thrombosis in COVID-19 Pneumonia. Journal of Cardiothoracic and Vascular Anesthesia, 2021, 35, 3631-3641.	0.6	46
71	Use of Polymerase Chain Reaction Assays of Aqueous Humor in the Differential Diagnosis of Retinitis in Patients Infected with Human Immunodeficiency Virus. Clinical Infectious Diseases, 1997, 24, 1100-1106.	2.9	45
72	Late Presenters in New HIV Diagnoses from An Italian Cohort of HIV-Infected Patients: Prevalence and Clinical Outcome. Antiviral Therapy, 2011, 16, 1103-1112.	0.6	45

#	Article	IF	Citations
73	Higher rates of tripleâ€class virological failure in perinatally <scp>HIV</scp>â€infected teenagers compared with heterosexually infected young adults in Europe. HIV Medicine, 2017, 18, 171-180.	1.0	45
74	Raltegravir, maraviroc, etravirine: an effective protease inhibitor and nucleoside reverse transcriptase inhibitor-sparing regimen for salvage therapy in HIV-infected patients with triple-class experience. Aids, 2010, 24, 924-928.	1.0	43
75	Role of brain biopsy in the management of focal brain lesions in HIV-infected patients. Neurology, 2000, 54, 993-997.	1.5	42
76	Triple-Class Virologic Failure in HIV-Infected Patients Undergoing Antiretroviral Therapy for Up to 10 Years. Archives of Internal Medicine, 2010, 170, 410-419.	4.3	42
77	Remission of AIDS-associated progressive multifocal leukoencephalopathy after cidofovir therapy. Journal of Neurology, 1999, 246, 723-725.	1.8	41
78	Trends in virological and clinical outcomes in individuals with HIV-1 infection and virological failure of drugs from three antiretroviral drug classes: a cohort study. Lancet Infectious Diseases, The, 2012, 12, 119-127.	4.6	41
79	Chronic Hepatitis B and C Virus Infection and Risk for Non-Hodgkin Lymphoma in HIV-Infected Patients. Annals of Internal Medicine, 2017, 166, 9.	2.0	41
80	Delayed HIV diagnosis and initiation of antiretroviral therapy. Aids, 2014, 28, 2297-2306.	1.0	39
81	Discontinuation of Initial Antiretroviral Therapy in Clinical Practice. Journal of Acquired Immune Deficiency Syndromes (1999), 2016, 71, 263-271.	0.9	39
82	Maraviroc is a substrate for OATP1B1 in vitro and maraviroc plasma concentrations are influenced by SLCO1B1 521 T>C polymorphism. Pharmacogenetics and Genomics, 2010, 20, 759-765.	0.7	38
83	Infectionâ€related and â€unrelated malignancies, <scp>HIV</scp> and the aging population. HIV Medicine, 2016, 17, 590-600.	1.0	37
84	Biobanking for COVID-19 research. Panminerva Medica, 2022, 64, .	0.2	36
85	Stranger Months: How SARS-CoV-2, Fear of Contagion, and Lockdown Measures Impacted Attendance and Clinical Activity During February and March 2020 at an Urban Emergency Department in Milan. Disaster Medicine and Public Health Preparedness, 2021, 15, e33-e42.	0.7	35
86	Respiratory Impairment Predicts Response to IL-1 and IL-6 Blockade in COVID-19 Patients With Severe Pneumonia and Hyper-Inflammation. Frontiers in Immunology, 2021, 12, 675678.	2.2	35
87	Immuno-Virological Discordance and the Risk of Non-AIDS and AIDS Events in a Large Observational Cohort of HIV-Patients in Europe. PLoS ONE, 2014, 9, e87160.	1.1	35
88	Enfuvirtide (Tâ€20) Crossâ€Reactive Glycoprotein 41 Antibody Does Not Impair the Efficacy or Safety of Enfuvirtide. Journal of Infectious Diseases, 2003, 188, 1827-1833.	1.9	34
89	Switching to unboosted atazanavir improves glucose tolerance in highly pretreated HIV-1 infected subjects. European Journal of Endocrinology, 2007, 156, 503-509.	1.9	34
90	Etravirine for the treatment of HIV infection. Expert Review of Anti-Infective Therapy, 2008, 6, 427-433.	2.0	34

#	Article	IF	Citations
91	Increased risk of virologic failure to the first antiretroviral regimen in HIV-infected migrants compared to natives: data from the ICONA cohort. Clinical Microbiology and Infection, 2016, 22, 288.e1-288.e8.	2.8	33
92	Evaluation of glomerular filtration rate in HIV-1-infected patients before and after combined antiretroviral therapy exposure*. HIV Medicine, 2011, 12, 4-13.	1.0	32
93	Regional Differences in AIDS and Non-AIDS Related Mortality in HIV-Positive Individuals across Europe and Argentina: The EuroSIDA Study. PLoS ONE, 2012, 7, e41673.	1.1	32
94	Factors associated with short-term changes in HIV viral load and CD4+ cell count in antiretroviral-naive individuals. Aids, 2014, 28, 1351-1356.	1.0	32
95	Viral clearance after early corticosteroid treatment in patients with moderate or severe covid-19. Scientific Reports, 2020, 10, 21291.	1.6	32
96	Remdesivir Versus Standard-of-Care for Severe Coronavirus Disease 2019 Infection: An Analysis of 28-Day Mortality. Open Forum Infectious Diseases, 2021, 8, ofab278.	0.4	31
97	Reversal of CSF positivity for JC virus genome by cidofovir in a patient with systemic lupus erythematosus and progressive multifocal leukoencephalopathy. Neurological Sciences, 2001, 22, 17-20.	0.9	30
98	Efficacy and safety of a switch to unboosted atazanavir in combination with nucleoside analogues in HIV-1-infected patients with virological suppression under antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2011, 66, 2372-2378.	1.3	30
99	Antiretroviral therapy in geriatric HIV patients: the GEPPO cohort study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2879-2886.	1.3	30
100	Impact of CD4 and CD8 dynamics and viral rebounds on loss of virological control in HIV controllers. PLoS ONE, 2017, 12, e0173893.	1.1	30
101	Tenâ€year survival among HIVâ€1â€infected subjects with AIDS or nonâ€AIDSâ€defining malignancies. International Journal of Cancer, 2012, 130, 2990-2996.	2.3	29
102	Survival and predictors of death in people with HIV-associated lymphoma compared to those with a diagnosis of lymphoma in general population. PLoS ONE, 2017, 12, e0186549.	1.1	29
103	Atazanavir/ritonavir with lamivudine as maintenance therapy in virologically suppressed HIV-infected patients: 96 week outcomes of a randomized trial. Journal of Antimicrobial Chemotherapy, 2018, 73, 1955-1964.	1.3	29
104	Influence of Geographical Origin and Ethnicity on Mortality in Patients on Antiretroviral Therapy in Canada, Europe, and the United States. Clinical Infectious Diseases, 2013, 56, 1800-1809.	2.9	28
105	Evolution of blood-associated HIV-1 DNA levels after 48 weeks of switching to atazanavir/ritonavir+lamivudine dual therapy versus continuing triple therapy in the randomized AtLaS-M trial. Journal of Antimicrobial Chemotherapy, 2017, 72, 2055-2059.	1.3	28
106	Analytical treatment interruption in chronic HIV-1 infection: time and magnitude of viral rebound in adults with 10 years of undetectable viral load and low HIV-DNA (APACHE study). Journal of Antimicrobial Chemotherapy, 2019, 74, 2039-2046.	1.3	28
107	Retrospective study on the outcome of two-drug regimens based on dolutegravir plus one reverse transcriptase inhibitor in virologically-suppressed HIV-infected patients. International Journal of Antimicrobial Agents, 2020, 55, 105893.	1.1	28
108	In vitro phenotypes to elvitegravir and dolutegravir in primary macrophages and lymphocytes of clonal recombinant viral variants selected in patients failing raltegravir. Journal of Antimicrobial Chemotherapy, 2013, 68, 2525-2532.	1.3	27

#	Article	IF	Citations
109	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL. Journal of Antimicrobial Chemotherapy, 2012, 67, 213-217.	1.3	26
110	Schistosomiasis, strongyloidiasis and Chagas disease: the leading imported neglected tropical diseases in Italy. Journal of Travel Medicine, 2020, 27, .	1.4	26
111	Impaired CD4 T-Cell Count Response to Combined Antiretroviral Therapy in Antiretroviral-Naive HIV-Infected Patients Presenting With Tuberculosis as AIDS-Defining Condition. Clinical Infectious Diseases, 2012, 54, 853-861.	2.9	25
112	Hyaluronic Acid Levels Predict Risk of Hepatic Encephalopathy and Liver-Related Death in HIV/Viral Hepatitis Coinfected Patients. PLoS ONE, 2013, 8, e64283.	1.1	25
113	Switching to dual/monotherapy determines an increase in CD8+ in HIV-infected individuals: an observational cohort study. BMC Medicine, 2018, 16, 79.	2.3	24
114	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 83, 240-250.	0.9	24
115	Incidence of deep venous thrombosis in COVID-19 hospitalized patients during the first peak of the Italian outbreak. Phlebology, 2021, 36, 375-383.	0.6	24
116	Clinical and immunological aspects of HIV infection in drug addicts. Clinical Immunology and Immunopathology, 1989, 50, S166-S176.	2.1	23
117	Higher plasma lopinavir concentrations are associated with a moderate rise in cholestasis markers in HIV-infected patients. Journal of Antimicrobial Chemotherapy, 2005, 56, 790-792.	1.3	23
118	The rate of accumulation of nonnucleoside reverse transcriptase inhibitor (NNRTI) resistance in patients kept on a virologically failing regimen containing an NNRTI[*]. HIV Medicine, 2012, 13, 62-72.	1.0	23
119	Number of daily pills, dosing schedule, selfâ€reported adherence and health status in 2010: a large crossâ€sectional study of <scp>HIV</scp>â€infected patients on antiretroviral therapy. HIV Medicine, 2013, 14, 153-160.	1.0	23
120	Immune activation and microbial translocation in liver disease progression in HIV/hepatitis co-infected patients: results from the Icona Foundation study. BMC Infectious Diseases, 2014, 14, 79.	1.3	23
121	Simplification to atazanavir/ritonavir monotherapy for HIV-1 treated individuals on virological suppression. Aids, 2014, 28, 2269-2279.	1.0	22
122	Antiretroviral resistance at virological failure in the NEAT 001/ANRS 143 trial: raltegravir plus darunavir/ritonavir or tenofovir/emtricitabine plus darunavir/ritonavir as first-line ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 1056-1062.	1.3	22
123	Bictegravir. Current Opinion in HIV and AIDS, 2018, 13, 326-333.	1.5	22
124	OUP accepted manuscript. Journal of Antimicrobial Chemotherapy, 2018, 73, 177-182.	1.3	22
125	Electrocardiographic changes in HIV-infected, drug-experienced patients being treated with atazanavir. Aids, 2007, 21, 1648-1651.	1.0	21
126	Inconsistent condom use among HIVâ€positive women in the â€œTreatment as Prevention Eraâ€• data from the Italian DIDI study. Journal of the International AIDS Society, 2013, 16, 18591.	1.2	21

#	Article	IF	Citations
127	Durability of first-line regimens including integrase strand transfer inhibitors (INSTIs): data from a real-life setting. Journal of Antimicrobial Chemotherapy, 2019, 74, 1363-1367.	1.3	21
128	Epicardial adipose tissue characteristics, obesity and clinical outcomes in COVID-19: A post-hoc analysis of a prospective cohort study. Nutrition, Metabolism and Cardiovascular Diseases, 2021, 31, 2156-2164.	1.1	21
129	Evolution patterns of raltegravir-resistant mutations after integrase inhibitor interruption. Clinical Microbiology and Infection, 2011, 17, 928-934.	2.8	20
130	Kaposi Sarcoma Risk in HIV-Infected Children and Adolescents on Combination Antiretroviral Therapy From Sub-Saharan Africa, Europe, and Asia. Clinical Infectious Diseases, 2016, 63, ciw519.	2.9	20
131	Darunavir for the treatment of HIV infection. Expert Opinion on Pharmacotherapy, 2018, 19, 1149-1163.	0.9	20
132	The NIQ of Lopinavir is Predictive of a 48-Week Virological Response in Highly Treatment-Experienced HIV-1-Infected Subjects Treated with a Lopinavir/Ritonavir-Containing Regimen. Antiviral Therapy, 2004, 9, 537-543.	0.6	20
133	Durability and Safety of a Novel Salvage Therapy in R5-Tropic HIV-Infected Patients: Maraviroc, Raltegravir, Etravirine. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e113-e115.	0.9	19
134	Mortality in migrants living with HIV in western Europe (1997â€“2013): a collaborative cohort study. Lancet HIV,the, 2015, 2, e540-e549.	2.1	19
135	Impact of social determinants on antiretroviral therapy access and outcomes entering the era of universal treatment for people living with HIV in Italy. BMC Public Health, 2018, 18, 870.	1.2	19
136	Evolution of major nonâ€HIVâ€related comorbidities in HIVâ€infected patients in the Italian Cohort of Individuals, NaÃ¯ve for Antiretrovirals (ICONA) Foundation Study cohort in the period 2004â€“2014. HIV Medicine, 2019, 20, 99-109.	1.0	19
137	Mediator release in cerebrospinal fluid of human immunodeficiency virus-positive patients with central nervous system involvement. Journal of Neuroimmunology, 1992, 38, 155-161.	1.1	18
138	Virological rebound in human immunodeficiency virus-infected patients with or without residual viraemia: results from an extended follow-up. Clinical Microbiology and Infection, 2013, 19, E542-E544.	2.8	18
139	CD4/CD8 Ratio and the Risk of Kaposi Sarcoma or Non-Hodgkin Lymphoma in the Context of Efficiently Treated Human Immunodeficiency Virus (HIV) Infection: A Collaborative Analysis of 20 European Cohort Studies. Clinical Infectious Diseases, 2021, 73, 50-59.	2.9	18
140	HIV-1 replication capacity and genotype changes in patients undergoing treatment interruption or lamivudine monotherapy. Journal of Medical Virology, 2008, 80, 201-208.	2.5	17
141	Detecting impaired glucose tolerance or type 2 diabetes mellitus by means of an oral glucose tolerance test in HIV-infected patients. HIV Medicine, 2011, 12, 109-117.	1.0	17
142	Identification of TRIM22 single nucleotide polymorphisms associated with loss of inhibition of HIV-1 transcription and advanced HIV-1 disease. Aids, 2013, 27, 2335-2344.	1.0	17
143	CD4 cell count response to first-line combination ART in HIV-2+ patients compared with HIV-1+ patients: a multinational, multicohort European study. Journal of Antimicrobial Chemotherapy, 2017, 72, 2869-2878.	1.3	17
144	Systemic inflammation markers after simplification to atazanavir/ritonavir plus lamivudine in virologically suppressed HIV-1-infected patients: ATLAS-M substudy. Journal of Antimicrobial Chemotherapy, 2018, 73, 1949-1954.	1.3	17

#	Article	IF	Citations
145	Oligoclonai IgG bands in cerebrospinal fluid and serum during asymptomatic human immunodeficiency virus infection. Annals of Neurology, 1988, 24, 277-279.	2.8	16
146	Evolutionary Characteristics of HIV Type 1 Variants Resistant to Protease Inhibitors in the Absence of Drug-Selective Pressure. AIDS Research and Human Retroviruses, 2003, 19, 1151-1153.	0.5	16
147	Inhibition of HIV replication by the plasminogen activator is dependent on vitronectin-mediated cell adhesion. Journal of Leukocyte Biology, 2007, 82, 1212-1220.	1.5	16
148	Predicting the magnitude of short-term CD4⁺ T-cell recovery in HIV-infected patients during first-line highly active antiretroviral therapy. Antiviral Therapy, 2010, 15, 165-175.	0.6	16
149	Use of statins and risk of AIDS-defining and non-AIDS-defining malignancies among HIV-1 infected patients on antiretroviral therapy. Aids, 2014, 28, 2407-2415.	1.0	16
150	Longitudinal analysis of HIV-1 coreceptor tropism by single and triplicate HIV-1 RNA and DNA sequencing in patients undergoing successful first-line antiretroviral therapy. Journal of Antimicrobial Chemotherapy, 2014, 69, 735-741.	1.3	16
151	Estimating Minimum Adult HIV Prevalence: A Cross-Sectional Study to Assess the Characteristics of People Living with HIV in Italy. AIDS Research and Human Retroviruses, 2015, 31, 282-287.	0.5	16
152	Reference curves for <scp>CD</scp>4 Tâ€cell count response to combination antiretroviral therapy in <scp>HIV</scp>â€1â€infected treatmentâ€naÃ¯ve patients. HIV Medicine, 2017, 18, 33-44.	1.0	16
153	HIV and tuberculosis: A historical perspective on conflicts and challenges. Tuberculosis, 2020, 122, 101921.	0.8	16
154	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatmentâ€“Experienced People Living With Human Immunodeficiency Virus. Clinical Infectious Diseases, 2021, 73, e2323-e2333.	2.9	16
155	Incidence of hypertension in people with HIV who are treated with integrase inhibitors versus other antiretroviral regimens in the RESPOND cohort consortium. HIV Medicine, 2022, 23, 895-910.	1.0	16
156	Amprenavir and ritonavir plasma concentrations in HIV-infected patients treated with fosamprenavir/ritonavir with various degrees of liver impairment. Journal of Antimicrobial Chemotherapy, 2007, 60, 831-836.	1.3	15
157	Associations of statins and antiretroviral drugs with the onset of type 2 diabetes among HIV-1-infected patients. BMC Infectious Diseases, 2017, 17, 43.	1.3	15
158	Presence of multiple genotypes in subjects with HPV-16 infection is highly associated with anal squamous intraepithelial lesions in HIV-1 infected males. PLoS ONE, 2017, 12, e0186367.	1.1	15
159	Access and response to direct antiviral agents (DAA) in HIV-HCV co-infected patients in Italy: Data from the Icona cohort. PLoS ONE, 2017, 12, e0177402.	1.1	15
160	Low compliance with hepatocellular carcinoma screening guidelines in hepatitis B/C virus coâ€infected HIV patients with cirrhosis. Journal of Viral Hepatitis, 2019, 26, 1224-1228.	1.0	15
161	First Italian Consensus Statement on Diagnosis, Prevention and Treatment of Cardiovascular Complications in HIV-infected Patients in the HAART Era (2006). Infection, 2007, 35, 134-142.	2.3	14
162	Integrase and Fusion Inhibitors Transmitted Drug Resistance in Naive Patients With Recent Diagnosis of HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e51-e53.	0.9	14

#	Article	IF	Citations
163	Viral tropism by geno2pheno as a tool for predicting CD4 decrease in HIV-1-infected naive patients with high CD4 counts. Journal of Antimicrobial Chemotherapy, 2012, 67, 1224-1227.	1.3	14
164	Incidence, Timing, and Determinants of Bacterial Pneumonia Among HIV-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2013, 63, 339-345.	0.9	14
165	Cardiovascular disease in women with HIV-1 infection. International Journal of Cardiology, 2017, 241, 50-56.	0.8	14
166	Timing of combined antiretroviral treatment initiation in male and female migrants living with HIV in Western Europe. Aids, 2017, 31, 835-846.	1.0	14
167	The extent of Bâ€cell activation and dysfunction preceding lymphoma development in <scp>HIV</scp>â€positive people. HIV Medicine, 2018, 19, 90-101.	1.0	14
168	Decreased frequencies of virus-specific T helper type 1 cells during interferon alpha plus ribavirin treatment in HIVâ€“hepatitis C virus co-infection. Aids, 2004, 18, 123-127.	1.0	13
169	Firstâ€line antiretroviral therapy with efavirenz plus tenofovir disiproxil fumarate/emtricitabine or rilpivirine plus tenofovir disiproxil fumarate/emtricitabine: a durability comparison. HIV Medicine, 2018, 19, 475-484.	1.0	13
170	Homeostatic model assessment for insulin resistance index trajectories in HIVâ€infected patients treated with different firstâ€line antiretroviral regimens. Journal of Medical Virology, 2019, 91, 1937-1943.	2.5	13
171	Prevalence and factors associated with HIV-1 multi-drug resistance over the past two decades in the Italian ARCA database. International Journal of Antimicrobial Agents, 2021, 57, 106252.	1.1	13
172	Role of blood pressure dysregulation on kidney and mortality outcomes in COVID-19. Kidney, blood pressure and mortality in SARS-CoV-2 infection. Journal of Nephrology, 2021, 34, 305-314.	0.9	13
173	Long-term efficacy and safety of fostemsavir among subgroups of heavily treatment-experienced adults with HIV-1. Aids, 2021, 35, 1061-1072.	1.0	13
174	Calendar Time Trends in the Incidence and Prevalence of Triple-Class Virologic Failure in Antiretroviral Drug-Experienced People With HIV in Europe. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 59, 294-299.	0.9	13
175	Pharmacokinetics of amprenavir given once or twice a day when combined with atazanavir in heavily pre-treated HIV-positive patients. Aids, 2003, 17, 2669-2671.	1.0	12
176	Steady-state pharmacokinetics of atazanavir given alone or in combination with saquinavir hard-gel capsules or amprenavir in HIV-1-infected patients. European Journal of Clinical Pharmacology, 2005, 61, 545-549.	0.8	12
177	Longitudinal evaluation of occult Hepatitis B infection in HIV-1 infected individuals during highly active antiretroviral treatment interruption and after HAART resumption. Infection, 2011, 39, 121-126.	2.3	12
178	Cost analysis of initial highly active antiretroviral therapy regimens for managing human immunodeficiency virus-infected patients according to clinical practice in a hospital setting. Therapeutics and Clinical Risk Management, 2013, 10, 9.	0.9	12
179	Efficacy and Safety Profile of Fostemsavir for the Treatment of People with Human Immunodeficiency Virus-1 (HIV-1): Current Evidence and Place in Therapy. Drug Design, Development and Therapy, 2022, Volume 16, 297-304.	2.0	12
180	Opening the door on entry inhibitors in HIV: Redefining the use of entry inhibitors in heavily treatment experienced and treatmentâ€limited individuals living with HIV. HIV Medicine, 2022, 23, 936-946.	1.0	12

#	Article	IF	Citations
181	Relation Between CD4 Cell Counts and HIV RNA Levels at Onset of Opportunistic Infections. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 44-48.	0.9	11
182	Pharmacokinetics of Two Randomized Trials Evaluating the Safety and Efficacy of Indinavir, Saquinavir and Lopinavir in Combination with Low-Dose Ritonavir: The MaxCmin1 and 2 Trials. Basic and Clinical Pharmacology and Toxicology, 2007, 101, 339-344.	1.2	11
183	Polyclonal serum-free light chains elevation in HIV-infected patients. Aids, 2012, 26, 2107-2110.	1.0	11
184	Long-term glucose tolerance in highly experienced HIV-infected patients receiving nucleoside analogue-sparing regimens. Aids, 2012, 26, 1837-1840.	1.0	11
185	Efficacy and safety in clinical practice of a rilpivirine, tenofovir and emtricitabine singleâ€tablet regimen in virologically suppressed HIVâ€positive patients on stable antiretroviral therapy. Journal of the International AIDS Society, 2015, 18, 20037.	1.2	11
186	Changing utilization of Stavudine (d4T) in HIVâ€positive people in 2006â€“2013 in the EuroSIDA study. HIV Medicine, 2015, 16, 533-543.	1.0	11
187	HIV DNA loads, plasma residual viraemia and risk of virological rebound in heavily treated, virologically suppressed HIV-infected patients. Clinical Microbiology and Infection, 2015, 21, 103.e7-103.e10.	2.8	11
188	Simplification to a dual regimen with darunavir/ritonavir plus lamivudine or emtricitabine in virologically-suppressed HIV-infected patients. Journal of Infection, 2016, 73, 619-623.	1.7	11
189	Incidence and progression to cirrhosis of new hepatitis C virus infections in persons living with human immunodeficiency virus. Clinical Microbiology and Infection, 2017, 23, 267.e1-267.e4.	2.8	11
190	Immune response to hepatitis B vaccination in HIV-positive individuals with isolated antibodies against hepatitis B core antigen: Results of a prospective Italian study. PLoS ONE, 2017, 12, e0184128.	1.1	11
191	Durability of different initial regimens in HIV-infected patients starting antiretroviral therapy with CD4+ counts <200 cells/mm3 and HIV-RNA >5 log10 copies/mL. Journal of Antimicrobial Chemotherapy, 2019, 74, 2732-2741.	1.3	11
192	Incidence and Predictors of Serological Treatment Response in Early and Late Syphilis Among People Living With HIV. Open Forum Infectious Diseases, 2019, 6, ofy324.	0.4	11
193	Evaluation of HIV Transmission Clusters among Natives and Foreigners Living in Italy. Viruses, 2020, 12, 791.	1.5	11
194	In vitro susceptibility to fostemsavir is not affected by long-term exposure to antiviral therapy in MDR HIV-1-infected patients. Journal of Antimicrobial Chemotherapy, 2020, 75, 2547-2553.	1.3	11
195	Mortality of HIV-Infected Patients with or without Cancer: Comparison with the General Population in Italy. Antiviral Therapy, 2012, 17, 447-458.	0.6	10
196	Immune recovery and T cell subset analysis during effective treatment with maraviroc. Journal of Antimicrobial Chemotherapy, 2012, 67, 2474-2478.	1.3	10
197	Nonâ€invasive fibrosis biomarkers â€“ <scp>APRI</scp> and <scp>F</scp>orns â€“ are associated with liver stiffness in <scp>HIV</scp>â€monoinfected patients receiving antiretroviral drugs. Liver International, 2013, 33, 1113-1120.	1.9	10
198	Development of a definition for Rapid Progression (RP) of renal function in HIV-positive persons: the D:A:D study. BMC Nephrology, 2014, 15, 51.	0.8	10

#	Article	IF	Citations
199	Triglyceride/HDL ratio and its impact on the risk of diabetes mellitus development during ART. Journal of Antimicrobial Chemotherapy, 2016, 71, 2663-2669.	1.3	10
200	Efficacy and tolerability of switching to a dual therapy with darunavir/ritonavir plus raltegravir in HIV-infected patients with HIV-1 RNA â‰¤50Âcp/mL. Infection, 2017, 45, 521-528.	2.3	10
201	Time spent with residual viraemia after virological suppression below 50 HIV-RNA copies/mL according to type of first-line antiretroviral regimen. International Journal of Antimicrobial Agents, 2018, 52, 492-499.	1.1	10
202	Switch to dolutegravir and unboosted atazanavir in HIV-1 infected patients with undetectable viral load and long exposure to antiretroviral therapy. Aids, 2019, 33, 1256-1260.	1.0	10
203	Susceptibility to HIV-1 integrase strand transfer inhibitors (INSTIs) in highly treatment-experienced patients who failed an INSTI-based regimen. International Journal of Antimicrobial Agents, 2020, 56, 106027.	1.1	10
204	Refining criteria for selecting candidates for a safe lopinavir/ritonavir or darunavir/ritonavir monotherapy in HIV-infected virologically suppressed patients. PLoS ONE, 2017, 12, e0171611.	1.1	10
205	Zidovudine and frequency of HIV-induced diffuse leukoencephalopathy. Lancet, The, 1991, 337, 1488.	6.3	9
206	Kappa light chain predominance in serum and cerebrospinal fluid from human immunodeficiency virus type 1 (HIV-1)-infected patients. Journal of Neuroimmunology, 1991, 32, 259-268.	1.1	9
207	Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir. Journal of Medical Virology, 2006, 78, 1537-1541.	2.5	9
208	Unexpected dramatic increase in CD4⁺ cell count in a patient with AIDS after enfuvirtide treatment despite persistent viremia and resistance mutations. Journal of Medical Virology, 2008, 80, 937-941.	2.5	9
209	Magnitude and Determinants of CD4 Recovery After HAART Resumption After 1 Cycle of Treatment Interruption. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 52, 588-594.	0.9	9
210	Pharmacokinetics of the raltegravir/maraviroc/etravirine combination. Journal of Antimicrobial Chemotherapy, 2011, 66, 1932-1934.	1.3	9
211	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infection. Journal of Antimicrobial Chemotherapy, 2017, 72, 632-633.	1.3	9
212	Elderly HIV-positive women: A gender-based analysis from the Multicenter Italian â€œGEPPOâ€•Cohort. PLoS ONE, 2019, 14, e0222225.	1.1	9
213	Establishing a hepatitis C continuum of care among <scp>HIV</scp>/hepatitis C virusâ€coinfected individuals in Euro<scp>SIDA</scp>. HIV Medicine, 2019, 20, 264-273.	1.0	9
214	Treatment outcomes of integrase inhibitors, boosted protease inhibitors and nonnucleoside reverse transcriptase inhibitors in antiretroviralâ€naÃ¯ve persons starting treatment. HIV Medicine, 2020, 21, 599-606.	1.0	9
215	Efficacy and safety of switching from branded to generic antiretrovirals in virologically suppressed HIV-infected patients. PLoS ONE, 2017, 12, e0182007.	1.1	9
216	Relation Between CD4 Cell Counts and HIV RNA Levels at Onset of Opportunistic Infections. Journal of Acquired Immune Deficiency Syndromes (1999), 2001, 27, 44-48.	0.9	8

#	Article	IF	Citations
217	The 118I Reverse Transcriptase Mutation Is the Only Independent Genotypic Predictor of Virologic Failure to a Stavudine-Containing Salvage Therapy in HIV-1-Infected Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2006, 41, 447-452.	0.9	8
218	Changes in Darunavir/r Resistance Score After Previous Failure to Tipranavir/r in HIV-1-Infected Multidrug-Resistant Patients. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 50, 192-195.	0.9	8
219	Etravirine plasma exposure is associated with virological efficacy in treatment-experienced HIV-positive patients. Antiviral Research, 2014, 108, 44-47.	1.9	8
220	Atazanavir/ritonavir monotherapy: 96 week efficacy, safety and bone mineral density from the MODAt randomized trial. Journal of Antimicrobial Chemotherapy, 2016, 71, 1637-1642.	1.3	8
221	Brief Report: Hyperbilirubinemia Is Associated With a Decreased Risk of Carotid Atherosclerosis in HIV-Infected Patients on Virological Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2018, 79, 617-623.	0.9	8
222	Pre-ART HIV-1 DNA in CD4+ T cells correlates with baseline viro-immunological status and outcome in patients under first-line ART. Journal of Antimicrobial Chemotherapy, 2018, 73, 3460-3470.	1.3	8
223	Virological response and retention in care according to time of starting ART in Italy: data from the Icona Foundation Study cohort. Journal of Antimicrobial Chemotherapy, 2020, 75, 681-689.	1.3	8
224	Rilpivirine plus cobicistat-boosted darunavir as a two-drug switch regimen in HIV-infected, virologically suppressed subjects on steady standard three-drug therapy: a randomized, controlled, non-inferiority trial (PROBEâ€‰2). Journal of Antimicrobial Chemotherapy, 2020, 75, 1332-1337.	1.3	8
225	Immunological and virological response to antiretroviral treatment in migrant and native men and women in Western Europe; is benefit equal for all?. HIV Medicine, 2018, 19, 42-48.	1.0	8
226	Virologic and immunologic outcomes of treatment with integrase inhibitors in a real-world setting: The RESPOND cohort consortium. PLoS ONE, 2020, 15, e0243625.	1.1	8
227	Slow Wave Sleep and Cyclic Alternating Pattern (CAP) in HIV-infected Asymptomatic Men. Sleep, 1995, , .	0.6	7
228	Impact of a treatment including tenofovir plus didanosine on the selection of the 65R mutation in highly drug-experienced HIV-infected patients. Aids, 2004, 18, 2205-2208.	1.0	7
229	Predictors of sustained response to therapy resumption after treatment interruption in HIV-infected patients failing antiretroviral therapy. Journal of Medical Virology, 2004, 72, 181-186.	2.5	7
230	Key questions in antiretroviral therapy: Italian Consensus Workshop (2005). Journal of Antimicrobial Chemotherapy, 2006, 57, 1055-1064.	1.3	7
231	Pharmacokinetic and pharmacodynamic determinants of early virological response to enfuvirtide-based regimens in HIV-positive patients. Journal of Antimicrobial Chemotherapy, 2008, 62, 384-387.	1.3	7
232	Italian Consensus Statement on Management of HIV-Infected Individuals with Advanced Disease NaÃ¯ve to Antiretroviral Therapy. Infection, 2009, 37, 270-82.	2.3	7
233	Predictors of CD4+ T-Cell Counts of HIV Type 1â€“Infected Persons After Virologic Failure of All 3 Original Antiretroviral Drug Classes. Journal of Infectious Diseases, 2013, 207, 759-767.	1.9	7
234	Evaluation of the Prognostic Value of Impaired Renal Function on Clinical Progression in a Large Cohort of HIV-Infected People Seen for Care in Italy. PLoS ONE, 2015, 10, e0124252.	1.1	7

#	Article	IF	Citations
235	Prognostic Value of the Fibrosis-4 Index in Human Immunodeficiency Virus Type-1 Infected Patients Initiating Antiretroviral Therapy with or without Hepatitis C Virus. PLoS ONE, 2015, 10, e0140877.	1.1	7
236	Pharmacokinetics of dolutegravir and rilpivirine in combination with simeprevir and sofosbuvir in HIV/hepatitis C virus-coinfected patients with liver cirrhosis. Journal of Antimicrobial Chemotherapy, 2016, 72, dkw492.	1.3	7
237	Host and disease factors are associated with cognitive function in European <scp>HIV</scp>â€infected adults prior to initiation of antiretroviral therapy. HIV Medicine, 2016, 17, 471-478.	1.0	7
238	The use of circulating cathodic antigen rapid test and serology for diagnosis of active Schistosoma mansoni infection in migrants in Italy, a non-endemic country: a cross sectional study. Memorias Do Instituto Oswaldo Cruz, 2017, 112, 452-455.	0.8	7
239	Population pharmacokinetics and pharmacogenetics of ritonavir-boosted darunavir in the presence of raltegravir or tenofovir disoproxil fumarate/emtricitabine in HIV-infected adults and the relationship with virological response: a sub-study of the NEAT001/ANRS143 randomized trial. Journal of Antimicrobial Chemotherapy, 2020, 75, 628-639.	1.3	7
240	T and B cell responses to cytomegalovirus antigens in healthy blood donors and bone marrow transplant recipients. FEMS Immunology and Medical Microbiology, 1993, 7, 55-62.	2.7	6
241	Sustained HIV RNA suppression after switching from enfuvirtide to etravirine in the early access programme. Journal of Antimicrobial Chemotherapy, 2009, 64, 1341-1344.	1.3	6
242	HIV RNA suppression rates after 24 weeks of treatment with etravirine, darunavir/ritonavir and raltegravir in the etravirine early access programme. International Journal of STD and AIDS, 2010, 21, 224-225.	0.5	6
243	Evolution of HIV-1 tropism at quasispecies level after 5 years of combination antiretroviral therapy in patients always suppressed or experiencing episodes of virological failure. Journal of Antimicrobial Chemotherapy, 2014, 69, 3085-3094.	1.3	6
244	Effectiveness, durability, and safety of darunavir/ritonavir in HIV-1-infected patients in routine clinical practice in Italy: a postauthorization noninterventional study. Drug Design, Development and Therapy, 2016, 10, 1589.	2.0	6
245	Estimated Glomerular Filtration Rate Trajectories in HIV-Infected Subjects Treated With Different Ritonavir-Boosted Protease Inhibitors and Tenofovir Disoproxil Fumarate or Abacavir. Medicine (United States), 2016, 95, e3780.	0.4	6
246	Cerebrospinal fluid analysis for HIV replication and biomarkers of immune activation and neurodegeneration in long-term atazanavir/ritonavir monotherapy treated patients. Medicine (United) Tj ETQq0 0 0 rgBT /Overlock 10 Tf	0.4	6
247	Durability and tolerability of first-line regimens including two nucleoside reverse transcriptase inhibitors and raltegravir or ritonavir boosted-atazanavir or -darunavir: data from the ICONA Cohort. HIV Clinical Trials, 2018, 19, 52-60.	2.0	6
248	Incidence of cancer and overall risk of mortality in individuals treated with raltegravirâ€based and nonâ€raltegravirâ€based combination antiretroviral therapy regimens. HIV Medicine, 2018, 19, 102-117.	1.0	6
249	Global temporal changes in the proportion of children with advanced disease at the start of combination antiretroviral therapy in an era of changing criteria for treatment initiation. Journal of the International AIDS Society, 2018, 21, e25200.	1.2	6
250	Pharmacotherapeutic management of HIV in transplant patients. Expert Opinion on Pharmacotherapy, 2019, 20, 1235-1250.	0.9	6
251	Brief Report: Outcome of Acute Hepatitis B Virus Infection in HIV-1â€“Infected Patients: Possible Factors Associated With Resolution or Chronicity. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 175-180.	0.9	6
252	Residual viremia in HIV-infected patients who continue a two-drug or switch to a three-drug integrase strand transfer inhibitor based regimen. Aids, 2021, 35, 1513-1516.	1.0	6

#	Article	IF	Citations
253	An update on integrase inhibitors: new opportunities for a personalized therapy? The NEXTaim Project. New Microbiologica, 2015, 38, 443-90.	0.1	6
254	Neutralizing monoclonal antibodies for the treatment and prophylaxis of SARS-CoV-2 infection. New Microbiologica, 2021, 44, 135-144.	0.1	6
255	Thallium-201 Single Photon Emission Computed Tomography in the Management of Contrast-Enhancing Brain Lesions in a Patient with AIDS. Clinical Infectious Diseases, 1996, 23, 185-186.	2.9	5
256	Raltegravir in treatment naÃ¯ve patients. European Journal of Medical Research, 2009, 14, 22.	0.9	5
257	Long-term CD4+ T-cell count evolution after switching from regimens including HIV nucleoside reverse transcriptase inhibitors (NRTI) plus protease inhibitors to regimens containing NRTI plus non-NRTI or only NRTI. BMC Infectious Diseases, 2011, 11, 23.	1.3	5
258	Viral rebound after switch to maraviroc/raltegravir dual therapy in highly experienced and virologically suppressed patients with HIV-1 infection. Journal of Antimicrobial Chemotherapy, 2014, 69, 1436-1439.	1.3	5
259	Switch of predicted HIV-1 tropism in treated subjects and its association with disease progression. Medicine (United States), 2016, 95, e5222.	0.4	5
260	Durability of switch regimens based on rilpivirine or on integrase inhibitors, both in association with tenofovir and emtricitabine, in HIV-infected, virologically suppressed patients. BMC Infectious Diseases, 2017, 17, 723.	1.3	5
261	Where is the greatest impact of uncontrolled HIV infection on AIDS and non-AIDS events in HIV?. Aids, 2018, 32, 205-215.	1.0	5
262	Rhodococcus defluvii pneumonia. Aids, 2019, 33, 2261-2263.	1.0	5
263	Patient-Reported Outcomes in an Observational Cohort of HIV-1-Infected Adults on Darunavir/Cobicistat-Based Regimens: Beyond Viral Suppression. Patient, 2020, 13, 375-387.	1.1	5
264	Long-Term Durability of Tenofovir-Based Antiretroviral Therapy in Relation to the Co-Administration of Other Drug Classes in Routine Clinical Practice. PLoS ONE, 2016, 11, e0160761.	1.1	5
265	Novelties in evaluation and monitoring of HIV-1 infection: Is standard virological suppression enough for measuring antiretroviral treatment success?. AIDS Reviews, 2017, 19, .	0.5	5
266	Redistribution of Human Immunodeficiency Virus Type 1 Variants Resistant to Protease Inhibitors after a Protease Inhibitor-Sparing Regimen. AIDS Research and Human Retroviruses, 2005, 21, 545-554.	0.5	4
267	Immunological Basis for IgE Hyper-Production in Enfuvirtide-Treated HIV- Positive Patients. Journal of Clinical Immunology, 2006, 26, 168-176.	2.0	4
268	Survival of HIV-1 Infected Multidrug-Resistant Patients Recycling Enfuvirtide After a Previous Failure. Journal of Acquired Immune Deficiency Syndromes (1999), 2009, 51, 179-184.	0.9	4
269	Viro-immunological dynamics in HIV-1-infected subjects receiving once-a-week emtricitabine to delay treatment change after failure: A pilot randomised trial. Journal of Clinical Virology, 2010, 47, 253-257.	1.6	4
270	Monotherapy With Atazanavir as a Simplificati Strategy. Journal of Acquired Immune Deficiency Syndromes (1999), 2012, 60, e101-e103.	0.9	4

#	Article	IF	Citations
271	Plasma fibroblast growth factor 23 and osteocalcin serum levels are associated with cardiovascular risk in HIV-1-infected patients receiving antiretroviral treatment. Journal of Antimicrobial Chemotherapy, 2013, 68, 2960-2963.	1.3	4
272	Atazanavir/ritonavir monotherapy as maintenance strategy in HIV-1 treated subjects with viral suppression: 96-week analysis results of the MODAT study. Journal of the International AIDS Society, 2014, 17, 19806.	1.2	4
273	Complexity and Dynamics of HIV-1 Chemokine Receptor Usage in a Multidrug-Resistant Adolescent. AIDS Research and Human Retroviruses, 2014, 30, 1243-1250.	0.5	4
274	Pregnancy Outcomes Among ART-Naive and ART-Experienced HIV-Positive Women. Journal of Acquired Immune Deficiency Syndromes (1999), 2014, 67, 258-267.	0.9	4
275	A survey of ATRIPLA use in clinical practice as first-line therapy in HIV-positive persons in Europe. Infection, 2014, 42, 757-762.	2.3	4
276	Optimal dietary calcium intake in HIV treated patients: No femoral osteoporosis but higher cardiovascular risk. Clinical Nutrition, 2014, 33, 363-366.	2.3	4
277	Incidence and factors associated with the risk of sexually transmitted diseases in <scp>HIV</scp>â€infected people seen for care in <scp>I</scp>taly: data from the <scp>I</scp>cona <scp>F</scp>oundation cohort. HIV Medicine, 2015, 16, 412-420.	1.0	4
278	Improved darunavir genotypic mutation score predicting treatment response for patients infected with HIV-1 subtype B and non-subtype B receiving a salvage regimen. Journal of Antimicrobial Chemotherapy, 2016, 71, 1352-1360.	1.3	4
279	Active HCV Replication but Not HCV or CMV Seropositive Status Is Associated With Incident and Prevalent Type 2 Diabetes in Persons Living With HIV. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 75, 465-471.	0.9	4
280	Awareness, discussion and non-prescribed use of HIV pre-exposure prophylaxis among persons living with HIV/AIDS in Italy: a Nationwide, cross-sectional study among patients on antiretrovirals and their treating HIV physicians. BMC Infectious Diseases, 2017, 17, 734.	1.3	4
281	Longâ€term effectiveness of recommended boosted protease inhibitorâ€based antiretroviral therapy in Europe. HIV Medicine, 2018, 19, 324-338.	1.0	4
282	Increased dose of Dolutegravir as a Potential Rescue Therapy in Multi-Experienced Patients. Antiviral Therapy, 2019, 24, 69-72.	0.6	4
283	Is physician assessment of alcohol consumption useful in predicting risk of severe liver disease among people with HIV and HIV/HCV co-infection?. BMC Public Health, 2019, 19, 1291.	1.2	4
284	Impact of diabetes on the risk of serious liver events and liver-related deaths in people living with HIV and hepatitis C co-infection: data from the ICONA Foundation Cohort Study. European Journal of Clinical Microbiology and Infectious Diseases, 2019, 38, 1857-1865.	1.3	4
285	Very High Pre-Therapy Viral Load is a Predictor of Virological Rebound in HIV-1-Infected Patients Starting a Modern First-Line Regimen. Antiviral Therapy, 2019, 24, 321-331.	0.6	4
286	Inflammation and microbial translocation measured prior to combination antiretroviral therapy (cART) and long-term probability of clinical progression in people living with HIV. BMC Infectious Diseases, 2021, 21, 557.	1.3	4
287	Does Syphilis Increase the Risk of HIV-RNA Elevation >200 Copies/mL in HIV-Positive Patients Under Effective Antiretroviral Treatment? Data From the ICONA Cohort. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 88, 132-137.	0.9	4
288	Long-term efficacy and safety of rilpivirine plus abacavir and lamivudine in HIV-1 infected patients with undetectable viral load. PLoS ONE, 2018, 13, e0191300.	1.1	4

#	Article	IF	Citations
289	Leronlimab (PRO 140) in vitro activity against 4-class drug resistant HIV-1 from heavily treatment experienced subjects. Pharmacological Research, 2022, 176, 106064.	3.1	4
290	Achieving virological control in pan-resistant HIV-1 infection: A case series. EBioMedicine, 2022, 77, 103906.	2.7	4
291	Diagnosis of Virus-associated Opportunistic Diseases of the Central Nervous System in Patients with HIV Infection by Polymerase Chain Reaction on Cerebrospinal Fluid. Annals of the New York Academy of Sciences, 1994, 724, 170-172.	1.8	3
292	Observational Study on HIV-Infected Subjects Failing HAART Receiving Tenofovir Plus Didanosine as NRTI Backbone. Infection, 2007, 35, 451-456.	2.3	3
293	In Vivo Treatment with Fusion Inhibitor Enfuvirtide Leads to Increased IL-12 Production by Autologous in Vitro Activated Monocytes from HIV-infected Individuals. Journal of Antivirals & Antiretrovirals, 2009, 01, 043-050.	0.1	3
294	Clinical, virologic, and immunologic outcomes in lymphoma survivors and in cancerâ€free, HIVâ€1â€“infected patients. Cancer, 2013, 119, 2710-2719.	2.0	3
295	Dolutegravir: a new option for HIV treatment. Future Virology, 2014, 9, 801-810.	0.9	3
296	The Association between Detected drug Resistance Mutations and CD4⁺T-Cell Decline in HIV-Positive Individuals Maintained on a Failing Treatment Regimen. Antiviral Therapy, 2018, 23, 105-116.	0.6	3
297	An observational, retrospective analysis evaluating switching to raltegravir plus abacavir/lamivudine in HIV-1-infected patients: the ORASWIRAL study. Infectious Diseases, 2018, 50, 220-222.	1.4	3
298	A nucleoside-sparing regimen of dolutegravir plus ritonavir-boosted atazanavir in HIV-1-infected patients with virological failure: the DOLATAV study . Drug Design, Development and Therapy, 2019, Volume 13, 477-479.	2.0	3
299	Brief Report: Association Between Low HIV-1 DNA and Western Blot Reactivity to HIV-1 Pol in Chronically Infected Individuals. Journal of Acquired Immune Deficiency Syndromes (1999), 2019, 82, 373-376.	0.9	3
300	Viro-immunological outcomes after 13-valent pneumococcal vaccination in HIV-1-infected individuals on stable virological suppression. Aids, 2019, 33, 1987-1994.	1.0	3
301	Simplification to High Genetic Barrier 2-Drug Regimens in People Living With HIV Harboring 4-Class Resistance Enrolled in the PRESTIGIO Registry. Journal of Acquired Immune Deficiency Syndromes (1999), 2020, 84, e24-e28.	0.9	3
302	Impact of Analytical Treatment Interruption on Burden and Diversification of HIV Peripheral Reservoir: A Pilot Study. Viruses, 2021, 13, 1403.	1.5	3
303	Integrase strand transfer inhibitor use and cancer incidence in a large cohort setting. Open Forum Infectious Diseases, 2022, 9, ofac029.	0.4	3
304	Boosted protease inhibitor-including versus a protease inhibitor-sparing regimen in protease inhibitor-resistant HIV-infected patients. Aids, 2004, 18, 821-823.	1.0	2
305	Predictors of lack of serological response to syphilis treatment in HIV-infected subjects. Journal of the International AIDS Society, 2014, 17, 19654.	1.2	2
306	An observational comparison of first-line combination antiretroviral treatment (cART) with 2NRTI and ATV/r or DRV/r in HIV-infected patients in Italy. Journal of the International AIDS Society, 2014, 17, 19771.	1.2	2

#	Article	IF	Citations
307	High-density lipoprotein-cholesterol levels and risk of cancer in HIV-infected subjects. Medicine (United States), 2016, 95, e4434.	0.4	2
308	Long-term effectiveness of unboosted atazanavir plus abacavir/lamivudine in subjects with virological suppression. Medicine (United States), 2016, 95, e5020.	0.4	2
309	Brief Report: Drop in CD4+ Counts Below 200 Cells/Î¼L After Reaching (or Starting From) Values Higher than 350 Cells/Î¼L in HIV-Infected Patients With Virological Suppression. Journal of Acquired Immune Deficiency Syndromes (1999), 2017, 76, 417-422.	0.9	2
310	Evolving treatment implementation among HIVâ€“infected pregnant women and their partners: results from a national surveillance study in Italy, 2001â€“2015. Journal of Global Health, 2017, 7, 010407.	1.2	2
311	Abacavir usage patterns and hypersensitivity reactions in the EuroSIDA cohort. HIV Medicine, 2018, 19, 252-260.	1.0	2
312	Immune activation, inflammation and HIV DNA after 96-weeks of ATV/r monotherapy: a MODAt substudy. Antiviral Therapy, 2018, 23, 633-637.	0.6	2
313	Stepping up HIV-1 low-level viraemia surveillance in South Africa. Lancet Infectious Diseases, The, 2018, 18, 130-131.	4.6	2
314	Changes in Homeostatic Model Assessment for Insulin Resistance (HOMA-IR) Index in Treated HIV-1 Infected People on Virological Suppression Who Switched to a Different Antiretroviral Regimen. Journal of Acquired Immune Deficiency Syndromes (1999), 2021, 87, e169-e173.	0.9	2
315	Levels of Alpha-Fetoprotein and Association with Mortality in Hepatocellular Carcinoma of HIV-1-Infected Patients. Journal of Oncology, 2022, 2022, 1-10.	0.6	2
316	Gas-exchange deficit and systemic hypoperfusion in COVID-19 and non-COVID-19 young adult patients with pneumonia. Panminerva Medica, 2024, 66, .	0.2	2
317	Viral antibodies in serum and cryoprecipitate of patients with essential mixed and secondary cryoglobulinemia preliminary results. Research in Clinic and Laboratory, 1986, 16, 345-8.	0.3	2
318	Crossâ€“sectional and retrospective questionnaire-trial to evaluate exercise habits in a sample of HIVâ€“infected individuals with type 2 diabetes mellitus. Sport Sciences for Health, 2005, 1, 81-90.	0.4	1
319	Effects of atazanavir/ritonavir and lopinavir/ritonavir on glucose uptake and insulin sensitivity. Aids, 2007, 21, 2366-2367.	1.0	1
320	Prior Therapy Influences the Efficacy of Lamivudine Monotherapy in Patients With Lamivudine-Resistant HIV-1 Infection. Journal of Acquired Immune Deficiency Syndromes (1999), 2011, 56, e34-e35.	0.9	1
321	No pol mutation is associated independently with the lack of immune recovery in patients infected with HIV and failing antiretroviral therapy. Journal of Medical Virology, 2011, 83, 391-398.	2.5	1
322	Unboosted atazanavir with lamivudine/emtricitabine for patients with long-lasting virological suppression. Journal of the International AIDS Society, 2014, 17, 19811.	1.2	1
323	Immortal time bias. Aids, 2015, 29, 860-861.	1.0	1
324	Efficacy of elvitegravir/cobicistat/emtricitabine/tenofovir disoproxil fumarate as treatment for primary or recent HIV infectionâ€”authorsâ€™ response. Journal of Antimicrobial Chemotherapy, 2017, 72, 1549-1550.	1.3	1

#	Article	IF	Citations
325	Cerebrospinal fluid viral replication and burden of resistance in three HIV-1-infected people taking Ibalizumab with multiple drug class-wide resistance. Aids, 2020, 34, 2152-2155.	1.0	1
326	Analysis of the faecal microbiome during analytical treatment interruption in people with chronic HIV infection and long-lasting virological suppression (APACHE study). Journal of Antimicrobial Chemotherapy, 2020, 75, 2700-2702.	1.3	1
327	Anti-HIV antibodies are representative of the latent reservoir but do not correlate with viral control in people with long-lasting virological suppression undergoing analytical treatment interruption (APACHE study). Journal of Antimicrobial Chemotherapy, 2021, 76, 1646-1648.	1.3	1
328	548. Baseline characteristics associated with clinical improvement and mortality in hospitalized patients with moderate COVID-19. Open Forum Infectious Diseases, 2020, 7, S340-S340.	0.4	1
329	Failure of on-demand pre-exposure prophylaxis: the risk of HIV drug resistance. Sexually Transmitted Infections, 2022, , sextrans-2021-055354.	0.8	1
330	Risk of HIV viral rebound in HIV infected patients on direct acting antivirals (DAAs) treatment for HCV. PLoS ONE, 2022, 17, e0262917.	1.1	1
331	Association between low levels of HIV-1 DNA and HLA class I molecules in chronic HIV-1 infection. PLoS ONE, 2022, 17, e0265348.	1.1	1
332	Association of high-risk sexual behaviours with sexually transmitted infections among men who have sex with men living with HIV. Sexually Transmitted Infections, 2022, , sextrans-2021-055365.	0.8	1
333	Long-Term Response in Patients Receiving HAART Including Nelfinavir: Experience from Two Italian Centers. Journal of Chemotherapy, 2002, 14, 189-193.	0.7	0
334	HIV protease inhibitors: present and future. Future Virology, 2011, 6, 571-580.	0.9	0
335	Residual viraemia does not influence 1 year virological rebound in HIV-infected patients with HIV RNA persistently below 50 copies/mL--authors' response. Journal of Antimicrobial Chemotherapy, 2012, 67, 2541-2542.	1.3	0
336	Determinants of access to experimental antiretroviral drugs in an Italian cohort of patients with HIV: a multilevel analysis. BMC Health Services Research, 2012, 12, 38.	0.9	0
337	Glucose tolerance in HIV-1 treated patients who switched from boosted-protease inhibitors to etravirine. Aids, 2013, 27, 2661-2663.	1.0	0
338	Is statin preventing cancer in HIV-1 infected individuals? An inappropriate methodology is a more likely explanation. Aids, 2015, 29, 857-859.	1.0	0
339	Switching antiretrovirals in older patients. Lancet HIV,the, 2019, 6, e640-e641.	2.1	0
340	Two-drug regimens with dolutegravir for maintaining viral suppression. Aids, 2019, 33, 2264-2266.	1.0	0
341	HIV-DNA undetectability during chronic HIV infection: frequency and predictive factors. Journal of Antimicrobial Chemotherapy, 2020, 75, 2994-2997.	1.3	0
342	Exercise ECG for coronary artery disease screening in people living with HIV. Aids, 2021, 35, 933-938.	1.0	0

#	Article	IF	Citations
343	Allogeneic bone marrow transplantation in HIV people with hematological malignancies: Postâ€transplant cyclophosphamide to overcome the HLAâ€matching barrier. Transplant Infectious Disease, 2021, 23, e13551.	0.7	0
344	Response to First-Line Ritonavir-Boosted Protease Inhibitors (PI/r)-Based Regimens in HIV Positive Patients Presenting to Care with Low CD4 Counts: Data from the Icona Foundation Cohort. PLoS ONE, 2016, 11, e0156360.	1.1	0
345	505. Impact of Remdesivir on SARS-CoV-2 Clearance in a Real-Life Setting: A Matched-Cohort Study. Open Forum Infectious Diseases, 2021, 8, S354-S355.	0.4	0
346	Optimizing HIV therapy. A consensus project on differences between cytidine analogues and regime compactness. New Microbiologica, 2014, 37, 285-306.	0.1	0